MétaCan
Menu
Back to cohort
Record W6976681771 · doi:10.60692/f32p8-r3m85

Oral abstracts of the 10th IAS Conference on HIV Science, 21‐24 July 2019, Mexico City, Mexico

2019· article· en· W6976681771 on OpenAlexaff

Bibliographic record

VenueGreater South Information System · 2019
Typearticle
Languageen
FieldMedicine
TopicPneumocystis jirovecii pneumonia detection and treatment
Canadian institutionsGlaxoSmithKline (Canada)
Fundersnot available
KeywordsRaltegravirEfavirenzClinical endpointTuberculosisRandomized controlled trialHuman immunodeficiency virus (HIV)

Abstract

fetched live from OpenAlex

Background: Double-dose raltegravir is recommended in HIV1infected patients with tuberculosis.A previous phase 2 study showed similar efficacy of standard raltegravir 400 mg BID, raltegravir 800 mg BID, or efavirenz-based regimens.We aimed to assess noninferiority of raltegravir 400 mg BID to efavirenz in HIV1-infected patients with tuberculosis.Methods: ANRS 12300 Reflate TB2 is an open-label, phase 3, randomized trial conducted in Brazil, Côte d'Ivoire, France, Mozambique, and Vietnam.ART-na€ ıve HIV1-infected patients aged ≥18 years on standard tuberculosis treatment for to weeks were randomized (1:1) to receive raltegravir 400 mg BID or efavirenz 600 mg QD both with TDF/3TC 300 mg/300 mg QD.The primary endpoint was the proportion of patients with virologic success at week 48 defined as HIV-RNA ≤50 cp/ml on allocated therapy using the FDA snapshot algorithm.The pre-specified non-inferiority margin was 12%.Results: From September 2015 to January 2018, 230 patients were randomized in each trial arm: 201 (87%) and 203 (88%) completed follow-up in the EFV and RAL arms, respectively.Median age was 35 (IQR: 2 to 3) years, 40% were female, median BMI 19.1 (IQR: 17. to 1.0) kg/m 2 , median CD4 102 (IQR: 38 to 239) cells/μL, median HIV-RNA was 5.5 log (IQR: 5.0 to 5.8), 311 (68%) patients had pulmonary tuberculosis only, and 308 (68%) had bacteriologically-confirmed tuberculosis.In the mITT population, virologic success was achieved: in 134/228 (59%) pts in the raltegravir arm and 135/227 (59%) pts in the efavirenz arm at W24 (end of TB treatment); in 139/ 228 (61%) patients in the raltegravir arm and 150/227 (66%) patients in the efavirenz arm at W48.At W48, the difference between the raltegravir and efavirenz arm was -5.1% (95% CI: -13.9-+3.7),thus not meeting criteria for non-inferiority.Sixty-two (27%) and 77 (33%) patients experienced grade 3 to 4 adverse events in the raltegravir and efavirenz arms, respectively (p = 0.1), including 11 (5%) and 13 (6%) IRIS (p = 0.7).Twelve (5%) patients in the raltegravir arm and 14 (6%) in the efavirenz arm died (Logrank p = 0.7).Conclusions: The non-inferiority of raltegravir 400 mg compared to efavirenz at week 48 was not demonstrated.Raltegravir remains a safe option in combination with tuberculosis treatment.Complementary analyses are necessary to identify determinants of virologic failures in both arms.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.001
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesInsufficient payload (model declined to judge)
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Not applicable · Consensus signal: Not applicable
GenreCandidate signal: Other · Consensus signal: Other
Teacher disagreement score0.431
Threshold uncertainty score0.811

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0010.001
Meta-epidemiology (narrow)0.0010.000
Meta-epidemiology (broad)0.0010.000
Bibliometrics0.0010.001
Science and technology studies0.0010.000
Scholarly communication0.0030.001
Open science0.0010.002
Research integrity0.0010.002
Insufficient payload (model declined to judge)0.4310.121

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.038
GPT teacher head0.242
Teacher spread0.204 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

Study designNot applicable
Domainnot available
GenreOther

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2019
Admission routes1
Has abstractyes

Explore more

Same venueGreater South Information SystemSame topicPneumocystis jirovecii pneumonia detection and treatmentFrench-language works237,207